GlassScriptPhysician profile
David August Schulte
NPI 1255680096
$5,959.97
in general payments reported to CMS, 2019-2025
31 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $1,030 · 2021: $1,341 · 2022: $912 · 2023: $890 · 2024: $892 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,854.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $792.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $564.35 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $460.34 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $360.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.55 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $234.93 | 2021-2025 | |
| Pfizer INC. | $161.91 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $143.39 | 2020-2025 | Verquvo, Gardasil, Gardasil 9 |
| Lundbeck LLC | $120.70 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $111.19 | 2022-2023 | |
| Amgen INC. | $101.99 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $97.88 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $81.97 | 2021-2024 | Livalo, Seglentis |
| Sanofi-Aventis U.S. LLC | $65.31 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $55.76 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $50.43 | 2022-2024 | Rexulti |
| Allergan, INC. | $39.91 | 2020 | |
| Janssen Pharmaceuticals, INC | $39.67 | 2023-2024 | Xarelto |
| Genentech USA, INC. | $35.79 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $30.87 | 2021 | |
| Phathom Pharmaceuticals, INC. | $29.43 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $28.70 | 2021 | |
| Exact Sciences Corporation | $27.56 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $27.07 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $21.21 | 2021 | |
| Abbott Laboratories | $16.30 | 2022 | |
| Mannkind Corporation | $16.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.88 | 2019 | |
| Axsome Therapeutics, INC. | $12.95 | 2025 | Auvelity |
| Dexcom, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.